![Geoff Meyerson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Geoff Meyerson
Directeur Général chez Locust Walk Securities LLC
Postes actifs de Geoff Meyerson
Sociétés | Poste | Début | Fin |
---|---|---|---|
Locust Walk Securities LLC
![]() Locust Walk Securities LLC Investment Banks/BrokersFinance Locust Walk Securities LLC is a securities brokerage firm headquartered in Boston, Massachusetts. The firm was founded by Geoffrey Meyerson and Joseph Mohr in 2011 and they are a subsidiary of Locust Walk Partners LLC. Locust Walk Securities serves as the broker-dealer for all Locust Walk engagements – enabling them to execute a wider range of securities-related transactions for their clients, which includes mergers and acquisitions, private placements and mezzanine financings, and partnerships involving equity investments. | Directeur Général | 01/01/2011 | - |
Fondateur | 01/01/2011 | - | |
Locust Walk Partners LLC
![]() Locust Walk Partners LLC Miscellaneous Commercial ServicesCommercial Services Locust Walk Partners LLC provides commercial supporting and advisory services. The firm involves in securities-related transactions for clients, including mergers and acquisitions, private placements & mezzanine financings and partnerships involving equity investments. The company was founded by Geoff Meyerson and Joseph Mohr in 2008 and is headquartered in Boston, MA. | Directeur Général | 01/12/2008 | - |
Fondateur | 01/12/2008 | - | |
Corporate Officer/Principal | 01/12/2008 | - |
Historique de carrière de Geoff Meyerson
Anciens postes connus de Geoff Meyerson
Sociétés | Poste | Début | Fin |
---|---|---|---|
AI Proteins, Inc.
![]() AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Directeur/Membre du Conseil | - | - |
Statistiques
Internationale
Etats-Unis | 4 |
Opérationnelle
Chief Executive Officer | 2 |
Founder | 2 |
Corporate Officer/Principal | 1 |
Sectorielle
Finance | 2 |
Commercial Services | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Locust Walk Securities LLC
![]() Locust Walk Securities LLC Investment Banks/BrokersFinance Locust Walk Securities LLC is a securities brokerage firm headquartered in Boston, Massachusetts. The firm was founded by Geoffrey Meyerson and Joseph Mohr in 2011 and they are a subsidiary of Locust Walk Partners LLC. Locust Walk Securities serves as the broker-dealer for all Locust Walk engagements – enabling them to execute a wider range of securities-related transactions for their clients, which includes mergers and acquisitions, private placements and mezzanine financings, and partnerships involving equity investments. | Finance |
Locust Walk Partners LLC
![]() Locust Walk Partners LLC Miscellaneous Commercial ServicesCommercial Services Locust Walk Partners LLC provides commercial supporting and advisory services. The firm involves in securities-related transactions for clients, including mergers and acquisitions, private placements & mezzanine financings and partnerships involving equity investments. The company was founded by Geoff Meyerson and Joseph Mohr in 2008 and is headquartered in Boston, MA. | Commercial Services |
AI Proteins, Inc.
![]() AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Health Technology |
- Bourse
- Insiders
- Geoff Meyerson
- Expérience